# Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

> **NCT02845297** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 67 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** Azacitadine

## Key facts

- **NCT ID:** NCT02845297
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2022-04
- **Final completion:** 2022-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2023-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02845297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02845297, "Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02845297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*